Anti-TNF-α Biotherapies: Perspectives for Evidence-Based Personalized Medicine
- 29 November 2012
- journal article
- research article
- Published by Taylor & Francis in Immunotherapy
- Vol. 4 (11) , 1167-1179
Abstract
This article discusses the rationale behind recommending immunopharmacological guidance of long-term therapies with genetically engineered anti-TNF-α immunoglobulin constructs. Arguments why therapeutic decision-making should not rely on clinical outcome alone are presented. Central to this is that the use of theranostics (i.e., monitoring circulating levels of functional anti-TNF-α drugs and antidrug antibodies) would markedly improve treatment because therapies can be tailored to individual patients and provide more effective and economical long-term therapies with minimal risk of side effects. Large-scale immunopharmacological knowledge of how patients 'handle' TNF-α biopharmaceuticals would also help industry develop more effective and safer TNF-α inhibitors.Keywords
Funding Information
- Danish Biotechnology Programme
This publication has 73 references indexed in Scilit:
- Differential effect of drug interference in immunogenicity assaysJournal of Immunological Methods, 2011
- The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanerceptAnnals of the Rheumatic Diseases, 2011
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a reviewArthritis Research & Therapy, 2010
- A novel method for the detection of antibodies to adalimumab in the presence of drug reveals “hidden” immunogenicity in rheumatoid arthritis patientsJournal of Immunological Methods, 2010
- Etanercept and venous thromboembolism: a case seriesJournal of Medical Case Reports, 2010
- Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodiesClinical and Experimental Immunology, 2008
- The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor α expression in the synoviumAnnals of the Rheumatic Diseases, 2008
- Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritisAnnals of the Rheumatic Diseases, 2007
- Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s diseaseGut, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006